epigallocatechin gallate has been researched along with Ovarian Neoplasms in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Fu, M; Guan, X; Huang, F; Huangfu, M; Li, X; Liu, H; Qin, J; Wang, J; Yu, D | 1 |
| Chen, HY; Chiang, YF; Hsia, SM; Huang, YJ; Wang, KL | 1 |
| Bimonte, S; Cascella, M | 1 |
| Lei, C; Mu, Z; Mun, LY; Xinqiang, S | 1 |
| Ang, WX; Bae, KH; Chung, JE; Gao, SJ; Kurisawa, M; Tan, S; Wang, S; Yamashita, A | 1 |
| Li, J; Qiao, X; Tian, D; Tian, M; Zhang, L | 1 |
| Araya-Farias, M; Bachvarov, D; Bairati, I; Bazinet, L; Doyen, A; Duchesne, T; Grégoire, J; Labbé, DP; Plante, M; Renaud, MC; Têtu, B; Trudel, D | 1 |
| Chang, Z; Fan, Q; Wang, F; Wang, L | 1 |
| Feng, Q; Jiang, P; Wang, P; Wang, X; Yang, CS | 2 |
| Chen, YC; Gao, Y; Rankin, GO; Tu, Y | 1 |
| Kalinovsky, T; Monterrey, JC; Niedzwiecki, A; Rath, M; Roomi, MW | 1 |
| Pagidas, K; Rao, SD | 1 |
| Beale, P; Huq, F; Yu, JQ; Yunos, NM | 1 |
| Chen, X; Shen, L; Yan, C; Yang, J | 1 |
| Bairati, I; Bazinet, L; Fradet, V; Labbé, DP; Têtu, B; Trudel, D | 1 |
| Beale, P; Chan, C; Huq, F; Mazumder, ME; Yu, JQ | 1 |
| Alvarez, RD; Chen, H; Landen, CN; Li, Y; Tollefsbol, TO | 1 |
| Ahn, WS; Bae, SM; Huh, SW; Kim, CK; Kim, SH; Kim, YW; Lee, IP; Lee, JM; Namkoong, SE | 1 |
| Chan, MM; Fong, D; Soprano, KJ; Weinstein, K | 1 |
| Wu, AH; Yu, MC | 1 |
| Albini, A; Bagnato, A; Decandia, S; Di Castro, V; Elia, G; Natali, PG; Rosanò, L; Spinella, F | 1 |
| Albini, A; Bagnato, A; Decandia, S; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F | 1 |
| Benghuzzi, H; Vance, S; Wilson-Simpson, F | 1 |
4 review(s) available for epigallocatechin gallate and Ovarian Neoplasms
| Article | Year |
|---|---|
Protective Effects of Epigallocatechin Gallate (EGCG) on Endometrial, Breast, and Ovarian Cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Catechin; Endometrial Neoplasms; Epithelial-Mesenchymal Transition; Female; Humans; NF-E2-Related Factor 2; Ovarian Neoplasms; Protective Agents; Tea | 2020 |
The Potential Roles of Epigallocatechin-3-Gallate in the Treatment of Ovarian Cancer: Current State of Knowledge.
Topics: Antineoplastic Agents, Phytogenic; Catechin; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2020 |
Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies.
Topics: Animals; Apoptosis; Carcinoma, Ovarian Epithelial; Catechin; Cell Line, Tumor; Cell Movement; Female; Humans; Incidence; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protective Agents; Tea | 2012 |
Tea, hormone-related cancers and endogenous hormone levels.
Topics: Animals; Breast Neoplasms; Catechin; Female; Hormones; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Risk Factors; Tea | 2006 |
1 trial(s) available for epigallocatechin gallate and Ovarian Neoplasms
| Article | Year |
|---|---|
A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Catechin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Tea | 2013 |
19 other study(ies) available for epigallocatechin gallate and Ovarian Neoplasms
| Article | Year |
|---|---|
PTEN/AKT/mTOR signaling mediates anticancer effects of epigallocatechin‑3‑gallate in ovarian cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Catechin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
Bioinformatics Analysis on Molecular Mechanism of Green Tea Compound Epigallocatechin-3-Gallate Against Ovarian Cancer.
Topics: Catechin; Computational Biology; Female; Gene Regulatory Networks; Humans; Ovarian Neoplasms; Protein Interaction Maps; Signal Transduction; Tea | 2017 |
Hyaluronic acid-green tea catechin micellar nanocomplexes: Fail-safe cisplatin nanomedicine for the treatment of ovarian cancer without off-target toxicity.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Catechin; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Carriers; Drug Liberation; Female; Humans; Hyaluronic Acid; Mice, SCID; Micelles; Nanoconjugates; Ovarian Neoplasms; Oxidative Stress; Particle Size; Surface Properties; Tea; Tissue Distribution | 2017 |
Modulation of Myb-induced NF-kB -STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors.
Topics: Antineoplastic Agents; Catechin; Cell Proliferation; Cisplatin; Curcumin; Drug Resistance, Neoplasm; Female; Humans; Isothiocyanates; NF-kappa B; Ovarian Neoplasms; Proto-Oncogene Proteins c-myb; Signal Transduction; STAT3 Transcription Factor; Sulfoxides | 2019 |
Epigallocatechin‑3‑gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase‑2.
Topics: Anticarcinogenic Agents; Carcinoma; Catechin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Female; Humans; Imidazoles; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Biosynthesis; Pyridines | 2014 |
EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer.
Topics: Animals; Catechin; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Copper Transporter 1; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Correction: EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer.
Topics: Antineoplastic Agents; Catechin; Cation Transport Proteins; Cisplatin; Copper Transporter 1; Female; Humans; Ovarian Neoplasms | 2015 |
Theaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways.
Topics: Biflavonoids; Carcinoma; Catechin; Cell Line, Tumor; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Oncogene Protein v-akt; Ovarian Neoplasms; Proto-Oncogene Proteins c-myc; Receptor, Notch1; Signal Transduction; Vascular Endothelial Growth Factor A | 2016 |
In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors.
Topics: Catechin; Cell Line, Tumor; Cytokines; Dose-Response Relationship, Drug; Doxycycline; Enzyme Induction; Female; Humans; Interleukin-1beta; Lipopolysaccharides; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Ovarian Neoplasms; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha; Uterine Cervical Neoplasms | 2010 |
Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells.
Topics: Anticarcinogenic Agents; Apoptosis; Catechin; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Humans; In Situ Nick-End Labeling; Ovarian Neoplasms | 2010 |
Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Catechin; Cisplatin; Curcumin; DNA Adducts; Drug Synergism; Female; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 2011 |
Inhibitory effect of Epigallocatechin gallate on ovarian cancer cell proliferation associated with aquaporin 5 expression.
Topics: Analysis of Variance; Anticarcinogenic Agents; Antioxidants; Apoptosis; Aquaporin 5; Catechin; Cell Line, Tumor; Cell Membrane; Cell Nucleus; Cell Proliferation; Cytoplasm; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; I-kappa B Proteins; NF-KappaB Inhibitor alpha; Ovarian Neoplasms; Pyrrolidines; RNA, Messenger; Thiocarbamates; Transcription Factor RelA | 2012 |
Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Catechin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; DNA Adducts; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Palladium | 2012 |
Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Catechin; Cell Cycle; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Isothiocyanates; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Sulfoxides; Telomerase; Thiocyanates; Tumor Cells, Cultured | 2013 |
Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Catechin; Cdc20 Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin A; Cyclin B; Cyclin B1; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; RNA, Messenger | 2004 |
Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility.
Topics: Antineoplastic Agents; Antioxidants; Catechin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cyclic N-Oxides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluoresceins; Humans; Hydrogen Peroxide; Ovarian Neoplasms; Pyruvic Acid; Spin Labels | 2006 |
Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target.
Topics: Antineoplastic Agents; Catechin; Cell Line, Tumor; Cyclooxygenase Inhibitors; Dinoprostone; Endothelin A Receptor Antagonists; Endothelin-1; Female; Humans; Ovarian Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Tea | 2006 |
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; bcl-X Protein; Caspase 3; Caspases; Catechin; Cell Proliferation; Endothelin-1; Enzyme Activation; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Receptor, Endothelin A; Signal Transduction; Tea; Transplantation, Heterologous; Urokinase-Type Plasminogen Activator; Vascular Endothelial Growth Factor A | 2006 |
Physiological responses of ES-2 ovarian cell line following administration of epigallocatechin-3-gallate (EGCG), thymoquinone (TQ), and selenium (SE).
Topics: Antineoplastic Agents; Antioxidants; Benzoquinones; Catechin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Neoplasm Proteins; Ovarian Neoplasms; Selenium | 2007 |